Teva Pharmaceuticals

Teva Intends to Divest API Business

Israeli generics manufacturer Teva Pharmaceuticals intends to divest its active pharmaceutical ingredient (API) business, Teva API (TAPI). A standalone business unit of Teva, TAPI supplies APIs to over 1,000 customers worldwide and has approximately 4,300 employees worldwide.

Teva Contemplates Selling $2 Billion Active Ingredients Division

Teva Pharmaceuticals considers selling its $2 billion active pharmaceutical ingredients (API) unit as part of its "Pivot to Growth" strategy.

Teva, Sun Pharma to Pay $2.15 Billion to Settle Pfizer Patent Suit

Judge Denies FDA Bid to Stay 'Morning-after' Pill Ruling

Teva's 2013 Forecast Is Below Wall Street Estimates

Teva Pharmaceutical Adjusted Profit Tops Estimates

U.S. Finds No Wrongdoing in Yasmin Patent Settlement

Teva Cuts Profit View on Weak European Markets

Egypt ETF Falls As Violence Spreads

Egypt Unrest Slams Middle East Investments in U.S.

Sanofi's Chris Viehbacher Sees Progress in Genzyme Talks

Novartis Starts Phase II Trial for Copy of Roche's Rituxan

Teva Pharm Q3 Profit Up, Beats Forecast